Literature DB >> 18019649

A rare case of thyroid haemangiosarcoma.

Paolo Del Rio1, Simona Cataldo, Lucia Sommaruga, Luigi Corcione, Anna Guazzi, Mario Sianesi.   

Abstract

The incidence of haemangiosarcoma in the literature is variable especially in the Alpine region and in Austria, ranging from 2 to 10% of all thyroid neoplastic lesions. This thyroid disease is characterised by positive endothelial markers (CD 31, CD 34 and FVIII), and co-positive markers for cytokeratins, epithelial membrane antigen and a loss of thyroglobulin can sometimes be found. Immunochemistry does not help the physician to classify the neoplasia as a variant of anaplastic carcinoma or sarcoma of endothelial origin. We present a case of epithelioid haemangiosarcoma in an elderly woman from outside the Alpine region with a contralateral papillary cancer treated by total thyroidectomy. The prognosis is poor and case reports are rare.

Entities:  

Mesh:

Year:  2007        PMID: 18019649

Source DB:  PubMed          Journal:  Chir Ital        ISSN: 0009-4773


  4 in total

Review 1.  Angiosarcoma of the thyroid: a case report with review of the literature.

Authors:  Arshpreet Kaur; Mukund S Didolkar; Asha Thomas
Journal:  Endocr Pathol       Date:  2013-09       Impact factor: 3.943

2.  Angiosarcoma of the thyroid.

Authors:  Petra Kalitova; Jan Plzak; Roman Kodet; Jaromir Astl
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-10-21       Impact factor: 2.503

3.  Primary thyroid angiosarcoma: an unusual localization.

Authors:  Pasquale Petronella; Marco Scorzelli; Rossella Luise; Giuseppe Iannaci; Patrizia Sapere; Marco Ferretti; Rosaria Maria Anna Costanzo; Fulvio Freda; Silvestro Canonico; Raffaele Rossiello
Journal:  World J Surg Oncol       Date:  2012-05-03       Impact factor: 2.754

4.  Primary Epithelioid Angiosarcoma of the Thyroid in a Patient Occupationally Exposed to Radiations.

Authors:  Michela Marina; Luigi Corcione; Maria Francesca Serra; Teore Ferri; Enrico Maria Silini; Graziano Ceresini
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-01       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.